{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:07:38Z","timestamp":1778684858277,"version":"3.51.4"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40120-026-00905-3","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:12:01Z","timestamp":1773252721000},"page":"1137-1154","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Atogepant for the Preventive Treatment of Migraine in Japanese Participants: A Phase\u00a03, Open-Label, 52-Week Extension Study"],"prefix":"10.1007","volume":"15","author":[{"given":"Yasuhiko","family":"Matsumori","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8698-941X","authenticated-orcid":false,"given":"Krisztian","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeya","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Takeshima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Forero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Ahmadyar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"de Abreu Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshimasa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"905_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1468-2982.1997.1701015.x","volume":"17","author":"F Sakai","year":"1997","unstructured":"Sakai F, Igarashi H. Prevalence of migraine in Japan: a nationwide survey. Cephalalgia. 1997;17:15\u201322. https:\/\/doi.org\/10.1046\/j.1468-2982.1997.1701015.x.","journal-title":"Cephalalgia"},{"issue":"4","key":"905_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/s1474-4422(24)00038-3","volume":"23","author":"JD Steinmetz","year":"2024","unstructured":"Steinmetz JD, Seeher KM, Schiess N, et al. Global, regional, and national burden of disorders affecting the nervous system, 1990\u20132021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. 2024;23(4):344\u201381. https:\/\/doi.org\/10.1016\/s1474-4422(24)00038-3.","journal-title":"Lancet Neurol"},{"key":"905_CR3","doi-asserted-by":"publisher","unstructured":"Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","DOI":"10.1177\/0333102417738202"},{"issue":"7","key":"905_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS, Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021\u201339. https:\/\/doi.org\/10.1111\/head.14153.","journal-title":"Headache"},{"issue":"9","key":"905_CR5","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1177\/0333102420919098","volume":"40","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Evers S. International classification of headache disorders - ICHD-4 alpha. Cephalalgia. 2020;40(9):887\u20138. https:\/\/doi.org\/10.1177\/0333102420919098.","journal-title":"Cephalalgia"},{"issue":"2","key":"905_CR6","doi-asserted-by":"publisher","first-page":"e293","DOI":"10.1097\/j.pain.0000000000002275","volume":"163","author":"S Safiri","year":"2022","unstructured":"Safiri S, Pourfathi H, Eagan A, et al. Global, regional, and national burden of migraine in 204 countries and territories, 1990 to 2019. Pain. 2022;163(2):e293\u2013309. https:\/\/doi.org\/10.1097\/j.pain.0000000000002275.","journal-title":"Pain"},{"issue":"1","key":"905_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, et al. Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain. 2020;21(1):137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0.","journal-title":"J Headache Pain"},{"issue":"5","key":"905_CR8","doi-asserted-by":"publisher","first-page":"422","DOI":"10.4065\/84.5.422","volume":"84","author":"DC Buse","year":"2009","unstructured":"Buse DC, Rupnow MFT, Lipton RB. Assessing and managing all aspects of migraine: migraine attacks, migraine-related functional impairment, common comorbidities, and quality of life. Mayo Clin Proc. 2009;84(5):422\u201335. https:\/\/doi.org\/10.4065\/84.5.422.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"905_CR9","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1111\/head.13613","volume":"59","author":"DC Buse","year":"2019","unstructured":"Buse DC, Fanning KM, Reed ML, et al. Life with migraine: effects on relationships, career, and finances from the Chronic Migraine Epidemiology and Outcomes (CaMEO) study. Headache. 2019;59(8):1286\u201399. https:\/\/doi.org\/10.1111\/head.13613.","journal-title":"Headache"},{"issue":"3","key":"905_CR10","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1177\/0333102410381145","volume":"31","author":"A Blumenfeld","year":"2010","unstructured":"Blumenfeld A, Varon S, Wilcox T, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2010;31(3):301\u201315. https:\/\/doi.org\/10.1177\/0333102410381145.","journal-title":"Cephalalgia"},{"key":"905_CR11","unstructured":"Araki N, Tagao T, Igarashi H, et al. Headache Treatment Guidelines 2021. Japanese Society of Neurological Therapeutics. https:\/\/www.jsnt.gr.jp\/guideline\/img\/zutsu_2021.pdf. Accessed Sept 15, 2025."},{"issue":"12","key":"905_CR12","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1177\/0333102419851855","volume":"39","author":"JL Meyers","year":"2019","unstructured":"Meyers JL, Davis KL, Lenz RA, Sakai F, Xue F. Treatment patterns and characteristics of patients with migraine in Japan: a retrospective analysis of health insurance claims data. Cephalalgia. 2019;39(12):1518\u201334. https:\/\/doi.org\/10.1177\/0333102419851855.","journal-title":"Cephalalgia"},{"issue":"1","key":"905_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s10194-019-1012-1","volume":"20","author":"K Ueda","year":"2019","unstructured":"Ueda K, Ye W, Lombard L, et al. Real-world treatment patterns and patient-reported outcomes in episodic and chronic migraine in Japan: analysis of data from the Adelphi migraine disease specific programme. J Headache Pain. 2019;20(1):68. https:\/\/doi.org\/10.1186\/s10194-019-1012-1.","journal-title":"J Headache Pain"},{"issue":"1","key":"905_CR14","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/ana.410330109","volume":"33","author":"PJ Goadsby","year":"1993","unstructured":"Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993;33(1):48\u201356. https:\/\/doi.org\/10.1002\/ana.410330109.","journal-title":"Ann Neurol"},{"issue":"2","key":"905_CR15","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/ana.410280213","volume":"28","author":"PJ Goadsby","year":"1990","unstructured":"Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol. 1990;28(2):183\u20137. https:\/\/doi.org\/10.1002\/ana.410280213.","journal-title":"Ann Neurol"},{"issue":"10","key":"905_CR16","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/0333102410368444","volume":"30","author":"JM Hansen","year":"2010","unstructured":"Hansen JM, Hauge AW, Olesen J, Ashina M. Calcitonin gene-related peptide triggers migraine-like attacks in patients with migraine with aura. Cephalalgia. 2010;30(10):1179\u201386. https:\/\/doi.org\/10.1177\/0333102410368444.","journal-title":"Cephalalgia"},{"key":"905_CR17","unstructured":"QULIPTA [atogepant]. Package Insert. AbbVie Inc.: 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/215206s011lbl.pdf. Accessed Oct 15, 2025."},{"key":"905_CR18","unstructured":"AQUIPTA [atogepant] 2024. Summary of Product Characteristics. https:\/\/www.medicines.org.uk\/emc\/product\/15049\/smpc. Accessed Oct 15, 2025."},{"key":"905_CR19","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1080\/17460441.2024.2365379","volume":"19","author":"C Baraldi","year":"2024","unstructured":"Baraldi C, Beier D, Martelletti P, et al. The preclinical discovery and development of atogepant for migraine prophylaxis. Expert Opin Drug Discov. 2024;19:783\u20138.","journal-title":"Expert Opin Drug Discov"},{"key":"905_CR20","unstructured":"AQUIPTA [atogepant]. Package Insert. AbbVie GK: 2026. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/ResultDataSetPDF\/112130_11900C2F3026_1_01. Accessed March 5, 2026"},{"issue":"9","key":"905_CR21","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/s1474-4422(20)30234-9","volume":"19","author":"PJ Goadsby","year":"2020","unstructured":"Goadsby PJ, Dodick DW, Ailani J, et al. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase\u00a02b\/3 trial. Lancet Neurol. 2020;19(9):727\u201337. https:\/\/doi.org\/10.1016\/s1474-4422(20)30234-9.","journal-title":"Lancet Neurol"},{"issue":"8","key":"905_CR22","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1056\/nejmoa2035908","volume":"385","author":"J Ailani","year":"2021","unstructured":"Ailani J, Lipton RB, Goadsby PJ, et al. Atogepant for the preventive treatment of migraine. N Engl J Med. 2021;385(8):695\u2013706. https:\/\/doi.org\/10.1056\/nejmoa2035908.","journal-title":"N Engl J Med"},{"issue":"4","key":"905_CR23","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/S1474-4422(24)00025-5","volume":"23","author":"C Tassorelli","year":"2024","unstructured":"Tassorelli C, Nagy K, Pozo-Rosich P, et al. Atogepant for the preventive treatment of episodic migraine in adults with prior inadequate responses to conventional oral preventive treatment (ELEVATE): a randomised, double-blind, placebo-controlled, parallel-group phase\u00a03b trial. Lancet Neurol. 2024;23(4):382\u201392. https:\/\/doi.org\/10.1016\/S1474-4422(24)00025-5.","journal-title":"Lancet Neurol"},{"issue":"9","key":"905_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251374569","volume":"45","author":"Y Matsumori","year":"2025","unstructured":"Matsumori Y, Yamada H, Nagaseki Y, et al. Atogepant for the preventive treatment of episodic migraine in Japanese participants: a phase\u00a02\/3, randomized, double-blind, placebo-controlled trial with an active treatment extension (RELEASE). Cephalalgia. 2025;45(9):03331024251374569.","journal-title":"Cephalalgia"},{"key":"905_CR25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/s0140-6736(23)01049-8","volume":"402","author":"P Pozo-Rosich","year":"2023","unstructured":"Pozo-Rosich P, Ailani J, Ashina M, et al. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2023;402:775\u201385. https:\/\/doi.org\/10.1016\/s0140-6736(23)01049-8.","journal-title":"Lancet"},{"issue":"1","key":"905_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/head.14439","volume":"63","author":"M Ashina","year":"2023","unstructured":"Ashina M, Tepper SJ, Reuter U, et al. Once-daily oral atogepant for the long-term preventive treatment of migraine: findings from a multicenter, randomized, open-label, phase\u00a03 trial. Headache. 2023;63(1):79\u201388. https:\/\/doi.org\/10.1111\/head.14439.","journal-title":"Headache"},{"issue":"1","key":"905_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/03331024221128250","volume":"43","author":"BC Klein","year":"2023","unstructured":"Klein BC, Miceli R, Severt L, et al. Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase\u00a03 ADVANCE trial. Cephalalgia. 2023;43(1):03331024221128250.","journal-title":"Cephalalgia"},{"issue":"8","key":"905_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/03331024251365206","volume":"45","author":"S Ashina","year":"2025","unstructured":"Ashina S, Ashina M, Holle-Lee D, et al. Long-term safety, efficacy and functional outcomes of atogepant for the preventive treatment of migraine. Cephalalgia. 2025;45(8):333102451365206.","journal-title":"Cephalalgia"},{"issue":"4","key":"905_CR29","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40615-015-0101-3","volume":"2","author":"A Baehr","year":"2015","unstructured":"Baehr A, Pe\u00f1a JC, Hu DJ. Racial and ethnic disparities in adverse drug events: a systematic review of the literature. J Racial Ethn Health Disparities. 2015;2(4):527\u201336. https:\/\/doi.org\/10.1007\/s40615-015-0101-3.","journal-title":"J Racial Ethn Health Disparities"},{"issue":"1","key":"905_CR30","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s40261-023-01327-x","volume":"44","author":"S Sakurai","year":"2024","unstructured":"Sakurai S, Matsui K, Narukawa M. Comparison of the incidence of adverse events between Japanese and non-Japanese healthy subjects in phase\u00a0I studies: a systematic review and meta-analysis. Clin Drug Investig. 2024;44(1):11\u20139. https:\/\/doi.org\/10.1007\/s40261-023-01327-x.","journal-title":"Clin Drug Investig"},{"issue":"1","key":"905_CR31","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/head.14229","volume":"62","author":"RB Lipton","year":"2022","unstructured":"Lipton RB, Gandhi P, Stokes J, et al. Development and validation of a novel patient-reported outcome measure in people with episodic migraine and chronic migraine: the Activity Impairment in Migraine Diary. Headache. 2022;62(1):89\u2013105. https:\/\/doi.org\/10.1111\/head.14229.","journal-title":"Headache"},{"key":"905_CR32","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.0000000000203615","volume":"100","author":"P Gandhi","year":"2023","unstructured":"Gandhi P, Lipton R, Dodick D, et al. Psychometric evaluation of the Activity Impairment in Migraine-Diary (AIM-D) using data from a phase\u00a03 (PROGRESS) clinical trial in patients with chronic migraine (P8-12.008). Neurology. 2023;100:3915. https:\/\/doi.org\/10.1212\/wnl.0000000000203615.","journal-title":"Neurology"},{"key":"905_CR33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1212\/WNL.96.15_supplement.1431","volume":"96","author":"P Gandhi","year":"2023","unstructured":"Gandhi P, Lipton R, Dodick D, et al. Psychometric evaluation of the Activity Impairment in Migraine-Diary (AIM-D) using data from a phase\u00a03 clinical trial (ADVANCE) in patients with episodic migraine (1431). Neurology. 2023;96:1431.","journal-title":"Neurology"},{"key":"905_CR34","doi-asserted-by":"publisher","unstructured":"Lipton RB, Pozo-Rosich P, Blumenfeld A, et al. Effect of atogepant for preventive migraine treatment on patient-reported outcomes in the randomized, double-blind, phase\u00a03 ADVANCE Trial. Neurology. 2023;100(8):e764-e777. https:\/\/doi.org\/10.1212\/WNL.0000000000201568.","DOI":"10.1212\/WNL.0000000000201568"},{"issue":"10","key":"905_CR35","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1111\/head.13652","volume":"59","author":"F Sakai","year":"2019","unstructured":"Sakai F, Takeshima T, Tatsuoka Y, et al. A randomized phase\u00a02 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache. 2019;59(10):1731\u201342. https:\/\/doi.org\/10.1111\/head.13652.","journal-title":"Headache"},{"issue":"8","key":"905_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068616","volume":"13","author":"K Hirata","year":"2023","unstructured":"Hirata K, Takeshima T, Sakai F, et al. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. BMJ Open. 2023;13(8):e068616. https:\/\/doi.org\/10.1136\/bmjopen-2022-068616.","journal-title":"BMJ Open"},{"key":"905_CR37","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1007\/s40264-021-01119-2","volume":"44","author":"F Sakai","year":"2021","unstructured":"Sakai F, Suzuki N, Ning X, et al. Long-term safety and tolerability of fremanezumab for migraine preventive treatment in Japanese outpatients: a multicenter, randomized, open-label study. Drug Saf. 2021;44:1355\u201364.","journal-title":"Drug Saf"},{"issue":"6","key":"905_CR38","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1080\/14740338.2021.1866536","volume":"20","author":"K Hirata","year":"2021","unstructured":"Hirata K, Takeshima T, Sakai F, et al. A long-term open-label safety study of galcanezumab in Japanese patients with migraine. Expert Opin Drug Saf. 2021;20(6):721\u201333. https:\/\/doi.org\/10.1080\/14740338.2021.1866536.","journal-title":"Expert Opin Drug Saf"},{"key":"905_CR39","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1007\/s40120-024-00663-0","volume":"13","author":"T Takeshima","year":"2024","unstructured":"Takeshima T, Yuasa A, Lloyd YM, et al. A discrete-choice experiment assessing the patient preferences and real-world experiences of patients with migraine in Japan. Neurol Ther. 2024;13:1661\u201383.","journal-title":"Neurol Ther"}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00905-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00905-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:07:39Z","timestamp":1778681259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00905-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["905"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00905-3","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by a local or central institutional review board at each participating institution and conducted in accordance with the International Conference for Harmonisation guidelines, applicable regulations, and the Declaration of Helsinki. Participants provided written informed consent before screening. The study is registered with ClinicalTrials.gov (NCT04437433).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Yasuhiko Matsumori reports personal consultancy fees from Amgen K.K., Astellas, BioPharma K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd. Akihiro Takahashi has received research funding\/collaborative research expenses AbbVie GK and Pfizer Japan Inc. Shigeya Tanaka has received lecture fees from Amgen K.K., Daiichi Sankyo Co. Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co. Ltd., and UCB Japan K.K., and has received collaborative research expenses from AbbVie GK, Amgen K.K., Eli Lilly Japan K.K., Lundbeck Japan K.K., Pfizer Japan Inc., and UCB Japan K.K. Takao Takeshima has been on the speakers\u2019 bureau for Amgen K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., and Otsuka Pharmaceutical Co., Ltd., and has received research funding\/collaborative research expenses from AbbVie GK., Amgen K.K., Eli Lilly Japan K.K., Eisai Co., Ltd., Lundbeck Japan K.K., and Pfizer Japan Inc. Takao Takeshima also acted as an advisor to Hedgehog MedTech, Inc., Sawai Pharmaceutical Co., Ltd., and TEIJIN Pharma Ltd. Toshimasa Yamamoto has received honoraria from Eisai Co., Ltd., and Takeda Pharmaceutical Co., Ltd. Jia Bao, Hua Guo, Gina Ahmadyar, Rosa de Abreu Ferreira, Giovanna Forero, and Krisztian Nagy are employees of AbbVie and may hold AbbVie stock.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}